News

PharmaEssentia Corporation (TWO: 6446) proudly announces its inaugural inclusion in the prestigious S&P Global Sustainability Yearbook, marking a significant milestone for Taiwan's biotechnology industry. As the first and the only one Taiwanese company in the biotech sector to be featured in this esteemed publication, PharmaEssentia's recognition underscores its proactive and outstanding performance in global Environmental, Social, and Governance (ESG) principles.   

The S&P Global Sustainability Yearbook serves as an authoritative guide to the world's leading companies' sustainable business practices. Each year, S&P rigorously evaluates thousands of companies worldwide across governance/economic, environmental, and social dimensions. Utilizing scores from the S&P Global 2023 Corporate Sustainability Assessment (CSA) to evaluate ESG performance and compile the S&P Global Sustainability Yearbook 2024, the 2024 edition covers assessments of 62 industries and over 9,400 companies globally, only 759 assessed companies are included in the 2024 S&P Global Sustainability Yearbook. 

For more information on the S&P Global 2024 Sustainability Yearbook, visit S&P Global Sustainability Yearbook. https://www.spglobal.com/esg/csa/yearbook/   

PharmaEssentia Sustainability Center has been actively engaged in the S&P Global Corporate Sustainability Assessment (CSA). S&P Global 2024 Sustainability Yearbook Biotechnology Industry Statistics :292 Biotechnology companies assessed; 10 Companies selected in the Year Book . In 2023, PharmaEssentia's ESG performance ranked 98 percentile globally within the biotech industry, became one of the ten companies selected in the 2024 Sustainability Year Book. PharmaEssentia also distinguished itself and became the first company from Taiwan to be featured in the S&P Global Sustainability Yearbook 2024. It stands as Taiwan's sole representative in the biotech sector, showcasing its outstanding ESG performance on a global scale.   

Driven by a clear commitment to advancing sustainable healthcare solutions, PharmaEssentia's Sustainability ESG Plan prioritizes innovation to enhance healthcare accessibility and affordability, aligning closely with Sustainable Development Goal 3. We are honored to be recognized in the S&P Global Sustainability Yearbook 2024. This achievement underscores our steadfast commitment to driving positive change in healthcare and reflects our ongoing efforts to integrate ESG principles into every facet of our operations. 

For further details on PharmaEssentia's approach to ESG sustainability, please visit PharmaEssentia ESG website. https://www.pharmaessentia-esg.com     

About PharmaEssentia Sustainability - ESG:   

PharmaEssentia is a leading biotechnology and bio-pharmaceutical company guided by the principles of Better Science, Better Lives. Specializing in research and development, PharmaEssentia is dedicated to bringing innovative drugs to market. Its flagship product, BESREMi®, a novel treatment for adults with Polycythemia Vera (PV) disease, has received regulatory approval in multiple countries, including the USA, Europe, Japan, and Taiwan. Committed to global health, PharmaEssentia extends its impact beyond drug development through strategic partnerships and support programs to ensure access for underserved patients worldwide.   

Aligned with its ESG initiatives, PharmaEssentia collaborates with international stakeholders to address healthcare challenges and mitigate climate change impacts. As the company expands its portfolio of world-class drugs, it remains steadfast in its commitment to corporate social responsibility, environmental sustainability, and creating enduring value for all stakeholders.   

For more information about PharmaEssentia Sustainability -ESG ,  

    please contact: Shu-Fen Li Senior Director, 

    PharmaEssentia Sustainability ESG Center Tel: +886 2 2655-7688 ext. 7839 

    Email: shufen_li@pharmaessentia.com